Quick Search 
Drugs of Today
Register or sign in

  
 
  
Drugs Today 2015, 51(4): 223
ISSN 1699-3993
Copyright 2015 Clarivate Analytics
CCC: 1699-3993
DOI: 10.1358/dot.2015.51.4.2320599
 
 
Apatinib: A promising oral antiangiogenic agent in the treatment of multiple solid tumors
Scott, A.J., Messersmith, W.A., Jimeno, A.
 
 
Aberrant proangiogenic pathways have long been implicated in tumorigenesis and metastasis. Antiangiogenic therapies have shown efficacy in the treatment of a variety of solid tumors including lung, breast, colon, glioblastomas, and other solid tumor types. Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), is an orally bioavailable agent currently being studied in multiple tumor types. Apatinib has shown a survival benefit in gastric cancer in a phase III trial and non-small cell lung cancer in a phase II trial. With a favorable side effect profile and improved outcomes, apatinib has demonstrated a substantial potential to augment therapeutic options in a variety of tumor types.


Full Text: PDF 
 
  



© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy